Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.49 |
| ▸ | HCAR3 | P49019 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | CNR1 | P21554 | 3/20 | 0.45 |
| ▸ | ACE2 | Q9BYF1 | 2/20 | 0.43 |
| ▸ | CNR2 | P34972 | 3/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | HRH2 | P25021 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23809463 | 0.86 | SLC22A12 (0.52) | SLC22A12HCAR3ALDH1A1ACE2KDM4E | |
| SCHEMBL23809350 | 0.82 | SLC22A12 (0.49) | SLC22A12ALDH1A1ACE2CNR2KDM4E | |
| SCHEMBL23809277 | 0.81 | SLC22A12 (0.47) | SLC22A12ALDH1A1CNR1ACE2CNR2 | |
| SCHEMBL23809337 | 0.80 | SLC22A12 (0.47) | SLC22A12ALDH1A1CNR1ACE2CNR2 | |
| SCHEMBL23809523 | 0.80 | SLC22A12 (0.51) | SLC22A12HCAR3ALDH1A1ACE2KDM4E | |
| SCHEMBL1554607 | 0.78 | ACE2 (0.51) | SLC22A12HCAR3ALDH1A1ACE2KDM4E | |
| SCHEMBL23809366 | 0.78 | SLC22A12 (0.45) | SLC22A12HCAR3ACE2KDM4EHPGD | |
| SCHEMBL23809421 | 0.76 | DYRK1A (0.40) | CNR1CNR2 | |
| SCHEMBL23809481 | 0.76 | SLC22A12 (0.53) | SLC22A12ALDH1A1CNR1ACE2CNR2 | |
| SCHEMBL13578013 | 0.75 | SLC22A12 (0.61) | SLC22A12HCAR3ALDH1A1CNR1PTGER4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210283138-A1 | SUBSTITUTED INDOLE MCL-1 INHIBITORS | VANDERBILT UNIVERSITY | 2021-09-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210283138-A1 | SUBSTITUTED INDOLE MCL-1 INHIBITORS | MCL1, BCL2L1, BCL9 | SLC22A12 3136/4885HCAR3 4325/4885ALDH1A1 2556/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.